Chronic Hepatitis B
Conditions
Brief summary
To compare the effectiveness, in a real world practice setting in tier 2 cities of China, of Entecavir (ETV) monotherapy and Lamivudine (LAM) based therapies (including LAM monotherapy, de novo LAM + Adefovir \[ADV\] combination, and early add-on of ADV) among chronic hepatitis B (CHB) patients who are naive to NUC at enrollment to this study
Detailed description
Sampling Method: Consecutive patient sampling Biospecimen Retention: Blood samples for HBV viral load testing along the treatment period of this study
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* CHB patients, or CHB patients with compensated cirrhosis, as defined by the current Chinese guidelines * Male or female * ≥ 18 years of age * Either Hepatitis B e antigen (HBeAg) positive or negative * Naïve to NUC (defined as no previous exposure to NUC treatment as based on patient self-report) * Has compensated liver disease * Patients with compensated cirrhosis * Patients who consent to participate in this study * Local residents with medical reimbursement coverage preferred
Exclusion criteria
* Co-infected with hepatitis C virus (HCV) * CHB patients with decompensated cirrhosis, liver failure, hepatocellular carcinoma, or any other types of malignancy at the screening phase * CHB patients who are being treated by interferon therapy within 6 months immediately prior to the screening phase of this study * CHB patients with a confirmed pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who achieve virology response (defined as HBV DNA < 300 copies/mL) by ETV monotherapy in comparison with LAM-based therapy | 48 weeks after initial NUC antiviral therapy | Virology response is defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) \< 300 copies/mL by a highly sensitive assay such as Roche COBAS or Abbott Real Time Polymerase chain reaction (PCR) performed in a one central laboratory |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who achieve virology response by ETV in comparison with LAM-based therapy after 24 weeks and 96 weeks of treatment (stratifying by the 3 LAM based subgroups) | 24 weeks and 96 weeks | — |
| Proportion of patients who modify their initial treatment options to manage suboptimal response or resistance after 24 weeks, 48 weeks, and 96 weeks of treatment among all treatment options | 24 weeks, 48 weeks and 96 weeks | — |
| Mean HBV DNA reductions after 48 weeks of treatment from baseline for ETV and LAM-based therapy patients (stratifying by the 3 LAM-based subgroups) | Baseline (Day 1) and 48 weeks | — |
| Cumulative incidence of patients who develop viral breakthrough and/or genotypic resistance | 24 weeks, 48 weeks, 72 weeks, 96 weeks, 144 weeks, 192 weeks and 240 weeks | — |
| Cumulative incidence of clinical outcome (eg, HCC, death, decompensated cirrhosis) in ETV arm versus LAM-based and other treatment arms | 48 weeks, 96 weeks, 144 weeks, 192 weeks and 240 weeks | — |
| Proportion of patients who achieve virology response among other treatment options, including ADV, LdT, and combinations of NUCs, after 24 weeks, 48 weeks, 72 weeks, 96 weeks, 144 weeks, 192 weeks and 240 weeks of treatment | 24 weeks, 48 weeks, 72 weeks, 96 weeks, 144 weeks, 192 weeks and 240 weeks | HBV DNA levels at week 24 will be analyzed at the laboratories of hospitals where the patients are treated while evaluation of HBV DNA levels after 48 and 96 weeks of treatment will be conducted at the central laboratory |
Countries
China
Outcome results
None listed